M. Shenin

SAT0328 An open-label study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

R. Neubauer, A. Schorpion, M. Shenin, 2017 .

A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.

M. Naik, C. Derk, Wen Xiong, 2009, Rheumatology.

Advances in disease-specific treatment of systemic sclerosis

M. Naik, C. Derk, M. Shenin, 2009 .

A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

R. Neubauer, C. Derk, A. Schorpion, 2018, BMC Rheumatology.

Gastric Antral Vascular Ectasia in Systemic Sclerosis: Demographics and Disease Predictors

V. Steen, C. Derk, M. O'Brien, 2010, The Journal of Rheumatology.

Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases

C. Derk, A. Mehta, A. Kebede, 2012, Rheumatology International.

Primary amyloidosis causing diffuse alveolar hemorrhage.

M. Naik, N. Sandorfi, M. Shenin, 2010, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis: reply

M. Naik, C. Derk, S. Schulz, 2010 .